Kiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) will be posting its quarterly earnings results before the market opens on Tuesday, April 23rd. Analysts expect Kiniksa Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.15. The company had revenue of $83.40 million for the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. On average, analysts expect Kiniksa Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA traded down $0.51 during trading on Wednesday, reaching $16.95. The company had a trading volume of 389,307 shares, compared to its average volume of 400,750. The stock’s fifty day moving average price is $19.61 and its 200 day moving average price is $17.97. Kiniksa Pharmaceuticals has a fifty-two week low of $10.65 and a fifty-two week high of $22.09. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of 94.17 and a beta of 0.27.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 5,126 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $383,242.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The disclosure for this sale can be found here. Insiders have sold 33,109 shares of company stock valued at $709,929 over the last quarter. Company insiders own 54.23% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at $60,000. Royal Bank of Canada lifted its position in shares of Kiniksa Pharmaceuticals by 44.2% in the second quarter. Royal Bank of Canada now owns 3,523 shares of the company’s stock valued at $50,000 after acquiring an additional 1,080 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at $59,000. Tower Research Capital LLC TRC increased its position in Kiniksa Pharmaceuticals by 437.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,915 shares of the company’s stock worth $53,000 after purchasing an additional 4,001 shares in the last quarter. Finally, State of Wyoming raised its stake in Kiniksa Pharmaceuticals by 41.1% in the 4th quarter. State of Wyoming now owns 7,160 shares of the company’s stock valued at $107,000 after purchasing an additional 2,087 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KNSA. Wedbush restated an “outperform” rating and issued a $30.00 target price (up previously from $28.00) on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, April 2nd. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.